NeuroChat with Dr. Karen Gregory

Craig W. Lindsley; Karen J. Gregory

doi:10.1021/acschemneuro.0c00183

NeuroChat with Dr. Karen Gregory

Craig W. Lindsley, Karen J. Gregory

Drug Discovery Biology

Research output: Contribution to journal › Editorial › Other › peer-review

Abstract

The NeuroChat series continues with a great Q&A with Dr. Karen Gregory from Monash University. Karen is an outstanding, world-leading neuropharmacologist and has published many seminal papers on mGlu receptors and allosteric modulation of GPCRs. After a postdoc in the United States at the VCNDD, Karen returned home as an Australian Research Council Future Fellow, level C Senior Research Fellow, equivalent to Associate Professor within the U.S. system. Never one to be idle, Karen co-leads the Endocrine and Neuropharmacology lab in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Sciences, and was recently appointed as the Therapeutic Program Area (Neuroscience) Coordinator to enhance multidisciplinary research and tackle the “big” challenges in neuroscience drug discovery. Karen brings unique insight of great value in the Q&A—I invite you to read the discussion below.

Original language	English
Pages (from-to)	1373-1375
Number of pages	3
Journal	ACS Chemical Neuroscience
Volume	11
Issue number	10
DOIs	https://doi.org/10.1021/acschemneuro.0c00183
Publication status	Published - 20 May 2020

Access to Document

10.1021/acschemneuro.0c00183Licence: CC BY

Cite this

@article{e152ec8f7e7f4563b7c4354ee11ef449,

title = "NeuroChat with Dr. Karen Gregory",

abstract = "The NeuroChat series continues with a great Q\&A with Dr. Karen Gregory from Monash University. Karen is an outstanding, world-leading neuropharmacologist and has published many seminal papers on mGlu receptors and allosteric modulation of GPCRs. After a postdoc in the United States at the VCNDD, Karen returned home as an Australian Research Council Future Fellow, level C Senior Research Fellow, equivalent to Associate Professor within the U.S. system. Never one to be idle, Karen co-leads the Endocrine and Neuropharmacology lab in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Sciences, and was recently appointed as the Therapeutic Program Area (Neuroscience) Coordinator to enhance multidisciplinary research and tackle the “big” challenges in neuroscience drug discovery. Karen brings unique insight of great value in the Q\&A—I invite you to read the discussion below.",

author = "Lindsley, \{Craig W.\} and Gregory, \{Karen J.\}",

year = "2020",

month = may,

day = "20",

doi = "10.1021/acschemneuro.0c00183",

language = "English",

volume = "11",

pages = "1373--1375",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - NeuroChat with Dr. Karen Gregory

AU - Lindsley, Craig W.

AU - Gregory, Karen J.

PY - 2020/5/20

Y1 - 2020/5/20

N2 - The NeuroChat series continues with a great Q&A with Dr. Karen Gregory from Monash University. Karen is an outstanding, world-leading neuropharmacologist and has published many seminal papers on mGlu receptors and allosteric modulation of GPCRs. After a postdoc in the United States at the VCNDD, Karen returned home as an Australian Research Council Future Fellow, level C Senior Research Fellow, equivalent to Associate Professor within the U.S. system. Never one to be idle, Karen co-leads the Endocrine and Neuropharmacology lab in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Sciences, and was recently appointed as the Therapeutic Program Area (Neuroscience) Coordinator to enhance multidisciplinary research and tackle the “big” challenges in neuroscience drug discovery. Karen brings unique insight of great value in the Q&A—I invite you to read the discussion below.

AB - The NeuroChat series continues with a great Q&A with Dr. Karen Gregory from Monash University. Karen is an outstanding, world-leading neuropharmacologist and has published many seminal papers on mGlu receptors and allosteric modulation of GPCRs. After a postdoc in the United States at the VCNDD, Karen returned home as an Australian Research Council Future Fellow, level C Senior Research Fellow, equivalent to Associate Professor within the U.S. system. Never one to be idle, Karen co-leads the Endocrine and Neuropharmacology lab in the Drug Discovery Biology theme at Monash Institute of Pharmaceutical Sciences, and was recently appointed as the Therapeutic Program Area (Neuroscience) Coordinator to enhance multidisciplinary research and tackle the “big” challenges in neuroscience drug discovery. Karen brings unique insight of great value in the Q&A—I invite you to read the discussion below.

UR - https://www.scopus.com/pages/publications/85084962389

U2 - 10.1021/acschemneuro.0c00183

DO - 10.1021/acschemneuro.0c00183

M3 - Editorial

C2 - 32429671

AN - SCOPUS:85084962389

SN - 1948-7193

VL - 11

SP - 1373

EP - 1375

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 10

ER -

NeuroChat with Dr. Karen Gregory

Abstract

Access to Document

Other files and links

Cite this